InsiderTrades

Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.

Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-27 · accession 0001628280-25-009091 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-28 2025-02-27 MDGL Sibold William John Pres, CEO, Dir M - OptEx — +50.0K 104.3K +92% —
D 2025-02-28 2025-02-27 MDGL Sibold William John Pres, CEO, Dir M - OptEx — -50.0K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-27 M A 50,000 — 104,303 D — — (F1) On February 27, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 2. Although the Issuer is irrevocably obligated to issue these shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on September 8, 2027, the fourth anniversary of the commencement of his employment with the Issuer.
2 Derivative Performance Restricted Stock Units 2025-02-27 M D 50,000 — 0 D — · — to — 50,000 Common Stock (F2) On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs.